Develops drugs for irritable bowel syndrome and chronic kidney disease.
Jun 2026Revenue $451M/yrExpenses $486M/yr
No trendCash runway over 10 years from Jun 2026
Figures by year
When will Ardelyx be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $451M and expenses $486M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $407M | $448M | −$41.0M |
| Dec 2024 | $334M | $362M | −$27.9M |
| Dec 2023 | $124M | $188M | −$63.3M |
| Dec 2022 | $52.2M | $116M | −$63.8M |
| Dec 2021 | $10.1M | $164M | −$154M |
| Dec 2020 | $7.57M | $98.4M | −$90.8M |
| Dec 2019 | $5.28M | $96.5M | −$91.3M |
| Dec 2018 | $2.61M | $93.6M | −$90.9M |
| Dec 2017 | $42.0M | $107M | −$65.1M |
| Dec 2015 | $24.0M | $53.4M | −$29.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.